

REMARKS

The specification has been amended to delete sequence information at pages 6-9 and to include the sequence information in the substitute Sequence Listing. The specification has been further amended to describe the oligonucleotide sequences at pages 35-103 by reference to nucleotide positions in SEQ ID NOS. 1-3. Support for the amendment of pages 35-103 may be found, for example, in the Sequence Listing as originally filed. The specification and claims have been amended to replace "<400>" references with proper references to sequence identification numbers. No new matter has been introduced by the foregoing amendment.

In view of the foregoing amendment, favorable consideration of Claims 1-44 is respectfully requested.

Pursuant to 37 C.F.R. §1.821(c) and (e) and the Notice to Comply dated October 20, 2000, Applicants submit herewith a Substitute Sequence Listing in paper and computer readable form.


I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), does not include new matter.

Applicants request a two-month extension of time pursuant to 37 C.F.R. §1.136(a) and enclose the required fee under 37 C.F.R. §1.17(a)(2). Please charge any additional fees or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

A copy of the Notice to Comply is enclosed.

Respectfully submitted,



---

Ronald B. Hildreth  
Patent Office Reg. No. 19,498

Janet M. MacLeod  
Patent Office Reg. No. 35,263

Attorneys for Applicants  
(212) 408-2597

Baker Botts, LLP  
30 Rockefeller Plaza  
44th Floor  
New York, NY 10112